The challenges of introducing routine G6PD testing into radical cure: a workshop report

@inproceedings{Ley2015TheCO,
  title={The challenges of introducing routine G6PD testing into radical cure: a workshop report},
  author={Benedikt Ley and Nick Luter and Fe Esperanza Espino and Angela Devine and Michael Kalnoky and Yoel Lubell and Kamala Thriemer and Jerry Kelcey Baird and Eugenie Poirot and Nolwenn Conan and Chong Chee Kheong and Lek Dysoley and Wasif Ali Zafarali Khan and April Grace Dion-Berboso and Germana Bancone and Jimee Hwang and R. A. ay Kumar and Ric N Price and Lorenz von Seidlein and Gonzalo J Domingo},
  booktitle={Malaria Journal},
  year={2015}
}
The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recommended routine testing of G6PD status prior… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency.

  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

for the treatment of malaria

WHO. Guideline
  • Geneva: World Health Organization;
  • 2015
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Report 2013

WHO. World Malari
  • Geneva: World Health Organization;
  • 2014
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…